<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Overview of the management of Crohn disease in children and adolescents
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Overview of the management of Crohn disease in children and adolescents
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Overview of the management of Crohn disease in children and adolescents
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Naamah Zitomersky, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Athos Bousvaros, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Melvin B Heyman, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alison G Hoppin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 01, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are five principal components of a program for management of Crohn disease (CD) in children and adolescents:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Medications
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Surgery
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nutritional rehabilitation and/or nutritional therapy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Psychosocial support
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Colorectal cancer screening for older patients
        </p>
        <p>
        </p>
        <p>
         Thus, treatment involves a multidisciplinary effort that includes the primary pediatrician or other primary care provider, pediatric gastroenterologist, adjunctive pediatric subspecialists (rheumatologist, ophthalmologist, dermatologist, and endocrinologist), surgeon, nutritionist, psychiatrist, gastrointestinal nurse specialist, pharmacologist, and social worker. For pediatric patients, the focus of this multidisciplinary team is not only on the patient but on the family members and others involved in the patient's care.
        </p>
        <p>
         This review focuses on the approach to selecting medications for an individual patient and other aspects of management, including exclusive enteral nutrition (EEN). Details about each of the medications are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/120380.html" rel="external">
          "Medical therapies for Crohn disease in children and adolescents"
         </a>
         .)
        </p>
        <p>
         Other aspects of the diagnosis and management of children with CD are discussed in separate topic reviews:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5879.html" rel="external">
          "Clinical presentation and diagnosis of inflammatory bowel disease in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5865.html" rel="external">
          "Clinical manifestations and complications of inflammatory bowel disease in children and adolescents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/96979.html" rel="external">
          "Important health maintenance issues for children and adolescents with inflammatory bowel disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5893.html" rel="external">
          "Growth failure and pubertal delay in children with inflammatory bowel disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          GENERAL APPROACH TO TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Overview of treatment decisions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of the ill patient with active CD involves an induction regimen that includes a potent therapy with a rapid onset of action  (
         <a class="graphic graphic_algorithm graphicRef64031" href="/z/d/graphic/64031.html" rel="external">
          algorithm 1
         </a>
         ). If a remission is achieved, the patient can be transitioned to a maintenance regimen using medications that are appropriate for long-term use  (
         <a class="graphic graphic_table graphicRef65046" href="/z/d/graphic/65046.html" rel="external">
          table 1
         </a>
         ). Anti-tumor necrosis factor (anti-TNF) antibodies (eg,
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13077" href="/z/d/drug information/13077.html" rel="external">
          adalimumab
         </a>
         ) can be used for both induction and maintenance due to their rapid onset of action. The selection of drugs for induction and maintenance depend on age, disease severity and location, and clinical course. A subset of very young children with inflammatory bowel disease (IBD) may have severe or refractory disease and are more likely to have an identifiable genetic cause of the disease (monogenic IBD). Treatment for those children with monogenic defects often differs from the immunosuppressive treatments below. (See
         <a class="medical medical_review" href="/z/d/html/5879.html" rel="external">
          "Clinical presentation and diagnosis of inflammatory bowel disease in children", section on 'Very early-onset inflammatory bowel disease'
         </a>
         .)
        </p>
        <p>
         In the past, clinicians have utilized two primary strategies ("step-up" or "top-down" therapy). These are being replaced by a third strategy: "treat-to-target" therapy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         "Step-up" therapy – Initiate treatment with a less potent immunosuppressive drug that may be effective in treating this patient's disease activity, and promptly step up therapy to a more potent drug if response is incomplete (usually after three to six months). We use this strategy for patients without risk factors for complicated disease or for those with mild disease activity. (See
         <a class="local">
          'Standard-risk patients'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         "Top-down" therapy – Initiate treatment with a potent immunosuppressant (eg, anti-TNF antibody) early in the course of the disease. We use this strategy for patients with high risks of complicated disease, such as extensive small bowel disease, severe ulcerating colonic disease, growth failure in mid- to late puberty, severe perianal disease, or steroid-unresponsive disease. Increasingly, a top-down strategy is being favored for moderate to severe disease, even without high-risk characteristics, because of the "treat-to-target" concept described below. (See
         <a class="local">
          'Moderate or severe'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         "Treat-to-target" therapy – With this approach, the goal is to achieve mucosal healing rather than resolution of clinical symptoms and laboratory abnormalities. The clinician and patient decide on an initial therapeutic approach for maintenance (eg, subcutaneous
         <a class="drug drug_pediatric" data-topicid="12595" href="/z/d/drug information/12595.html" rel="external">
          methotrexate
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12582" href="/z/d/drug information/12582.html" rel="external">
          6-mercaptopurine
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         ), based on a combination of clinical parameters (disease severity) and patient preference. At some fixed time point in the future (eg, 6 to 12 months after the start of treatment), the patient undergoes a complete reassessment, such as imaging or colonoscopy, as clinically indicated. If the bowel has healed, the patient continues on the current treatment. If the bowel remains inflamed, other therapeutic options are considered.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1776590380">
         <span class="h2">
          Treatment goals
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal goal for treatment has not been established. Increasingly, a "treat-to-target" approach is used, in which the goal is to achieve mucosal healing (based on objective measures such as serial magnetic resonance imaging [MRI], upper endoscopy, or colonoscopy with biopsies), rather than a goal of resolution of clinical symptoms and laboratory abnormalities (see
         <a class="local">
          'Overview of treatment decisions'
         </a>
         above) [
         <a href="#rid1">
          1
         </a>
         ]. This is because endoscopic healing is poorly correlated with clinical symptoms and/or laboratory values. Patients who feel well may still have endoscopic or radiologic evidence of inflammation, and there is some evidence that subclinical inflammation increases the risk for future exacerbations or the development of complications, such as strictures, fistulas, and abscesses [
         <a href="#rid2">
          2,3
         </a>
         ]. The rationale for this aggressive "treat-to-target" approach is that healing the intestinal mucosa may result in better long-term outcomes for pediatric IBD, including fewer complications and surgeries. This potential benefit has not been proven, but, if true, it would balance the costs and burden of the endoscopic and radiographic monitoring procedures. A panel of experts (the STRIDE-II initiative) has developed a list of "preferred targets" in IBD, including clinical remission, biochemical remission, and endoscopic healing [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         Achieving mucosal healing typically requires long-term immunosuppressive therapy, so the goal of improved mucosal healing must be balanced against the potential risks of the specific medication. Thus, in addition to monitoring closely for drug efficacy, the clinician must monitor for drug toxicities and medication adherence.
        </p>
        <p class="headingAnchor" id="H4051861736">
         <span class="h2">
          Duration of maintenance therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with moderate to severe CD who achieve mucosal healing with biologic and/or immunomodulator therapy, the optimal duration of treatment is unclear. However, many such patients will require lifelong therapy with at least one agent.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Withdrawal of immunomodulator
         </strong>
         – For those who achieve remission with combination biologic and immunomodulator therapy (eg,
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         with
         <a class="drug drug_pediatric" data-topicid="12582" href="/z/d/drug information/12582.html" rel="external">
          mercaptopurine
         </a>
         ), the relative risks and benefits of withdrawing the immunomodulator are unclear and the decision requires detailed discussion and shared decision-making with the patient and family. (See
         <a class="medical medical_review" href="/z/d/html/120380.html" rel="external">
          "Medical therapies for Crohn disease in children and adolescents", section on 'Anti-TNF monotherapy versus combination therapy with an immunomodulator'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Withdrawal of biologic agent
         </strong>
         – For patients who achieve mucosal healing on a biologic agent (with or without an immunomodulator), we generally suggest continuing the biologic agent as long as the medication is effective at controlling the disease and maintaining quality of life and there are no significant adverse effects. Disease relapse rates are high following withdrawal of a biologic agent. As an example, in a study of children with CD who achieved mucosal and histologic healing with anti-TNF therapy, nearly one-half (13 of 24 patients) experienced relapse after changing to an immunomodulator (median follow-up 29 months) [
         <a href="#rid5">
          5
         </a>
         ]. Similar outcomes are seen in studies in adults with CD. (See
         <a class="medical medical_review" href="/z/d/html/16224.html" rel="external">
          "Medical management of moderate to severe Crohn disease in adults", section on 'Duration of maintenance therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          ASSESSMENT OF DISEASE ACTIVITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The response to therapy is based upon the clinician's evaluation of clinical disease activity and supporting laboratory data, assessed during clinical visits approximately every three to four months. Very stable patients can be assessed twice a year.
        </p>
        <p>
         Objective assessments, including follow-up magnetic resonance imaging (MRI), upper endoscopy, or colonoscopy, are increasingly used to monitor disease progression and guide treatment decisions; this is known as a treat-to-target approach. (See
         <a class="local">
          'Treatment goals'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1252945866">
         <span class="h2">
          Clinical assessment
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinician should monitor clinical symptoms including diarrhea, abdominal pain, anorexia, growth failure, fatigue, extraintestinal symptoms, school attendance, and psychological stress (eg, anxiety and/or depression). The examination evaluates for signs of abdominal, perianal, dermatologic, and rheumatologic illness. Weight and height are measured at each visit, and the interval height velocity is calculated. Height percentiles should also be interpreted in the context of the child's genetic potential, usually estimated based on the midparental height. Screening and assessing children for growth failure is an essential component of medical care and is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5893.html" rel="external">
          "Growth failure and pubertal delay in children with inflammatory bowel disease"
         </a>
         .)
        </p>
        <p>
         For clinical care, disease severity usually is determined by the clinician's global assessment. Note that this assessment is not standardized, although a scoring system may be used to capture some components (see
         <a class="local">
          'Systems for scoring disease activity'
         </a>
         below). Moreover, clinical symptoms do not always correlate with the degree of laboratory or endoscopic inflammation [
         <a href="#rid1">
          1
         </a>
         ]. The following are
         <strong>
          examples
         </strong>
         of a typical patient in each category but are not prescriptive:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mild
         </strong>
         – Patient has mild, brief episodes of abdominal pain and loose stools (with or without small amounts of visible blood), little or no anemia, and no weight loss or growth delay. There is no abdominal tenderness on examination. Endoscopy and imaging demonstrate either limited disease (eg, terminal ileitis) or mild disease (eg, a few aphthae in the colon). Noncaseating granulomas may be present. Extraintestinal manifestations usually are not present.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Moderate
         </strong>
         – Patient has frequent episodes of abdominal pain that interfere with activities and five or more loose stools daily (with or without visible blood). Weight and height gain are less than expected for age or as compared with the patient's previous trajectory. Patients may have fatigue, mild or moderate anemia, elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), and a somewhat tender abdomen on examination. Radiography and endoscopy demonstrate more extensive or severe disease, such as ulcers throughout the colon, extensive ileal involvement, or significant upper gastrointestinal tract involvement. Extraintestinal manifestations of inflammatory bowel disease (IBD) may be present, such as erythema nodosum, arthritis, or uveitis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severe
         </strong>
         – Patient has frequent abdominal pain and liquid stools, including at night, and feels fatigued. There is marked abdominal tenderness, with guarding or a mass. A history of weight loss is common, and body mass index is often &lt;10
         <sup>
          th
         </sup>
         percentile. There is moderate or severe anemia, elevated ESR, elevated CRP, hypoalbuminemia, malnutrition, and definite growth failure. On endoscopy, deep fissuring ulcers and longitudinal ulcers may be seen throughout the ileum and colon. Extensive small bowel disease (Paris classification L4b) may be present  (
         <a class="graphic graphic_figure graphicRef89025" href="/z/d/graphic/89025.html" rel="external">
          figure 1
         </a>
         and
         <a class="graphic graphic_table graphicRef89028" href="/z/d/graphic/89028.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p>
         The presence of perianal fistulas or extraintestinal manifestations of IBD (eg, arthritis, fever, uveitis, erythema nodosum) increase the severity assessment. Fatigue is a common symptom, both at clinical presentation and in follow-up. Some fatigue may be associated with disease activity since it tends to improve with treatment directed at the IBD in placebo-controlled trials [
         <a href="#rid6">
          6
         </a>
         ]. Other possible causes of fatigue include anemia, emotional distress, and sleep disturbance [
         <a href="#rid6">
          6,7
         </a>
         ]. The clinician should specifically ask about fatigue during routine monitoring of patients with IBD and address the various contributors as part of management.
        </p>
        <p class="headingAnchor" id="H828643565">
         <span class="h2">
          Laboratory tests
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Routine tests
         </strong>
         – The laboratory assessment usually includes a complete blood count (CBC), serum albumin, ESR, CRP, and liver aminotransferases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]). There is some evidence that fecal calprotectin levels or other fecal markers of inflammation are correlated with disease activity and can be a useful adjunct to the clinical and laboratory evaluation of the patient [
         <a href="#rid1">
          1,8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5879.html" rel="external">
          "Clinical presentation and diagnosis of inflammatory bowel disease in children", section on 'Laboratory features'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Conditional tests
         </strong>
         – Additional testing depends on the clinical course of the patient. In some patients, particularly those with active disease or on prolonged glucocorticoid therapy, we measure ferritin and iron levels, vitamin D, vitamin B12, and zinc levels and assess skeletal health using bone densitometry periodically  (
         <a class="graphic graphic_table graphicRef66288" href="/z/d/graphic/66288.html" rel="external">
          table 3
         </a>
         ). If ALT and AST are elevated, we check gamma-glutamyl transpeptidase (GGTP) to assess for the unusual complication of primary sclerosing cholangitis; some providers monitor GGTP routinely, along with ALT and AST. A low alkaline phosphatase level should prompt assessment of zinc status. (See
         <a class="medical medical_review" href="/z/d/html/96979.html" rel="external">
          "Important health maintenance issues for children and adolescents with inflammatory bowel disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5887.html" rel="external">
          "Vitamin and mineral deficiencies in inflammatory bowel disease", section on 'Laboratory monitoring for nutrient deficiencies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients presenting with a flare of colitis, we screen for bacterial causes of colitis, with stool cultures and testing for
         <em>
          Clostridioides
         </em>
         <em>
          difficile
         </em>
         toxin; for those with refractory colitis, we also evaluate for infection with cytomegalovirus (CMV). (See
         <a class="medical medical_review" href="/z/d/html/5879.html" rel="external">
          "Clinical presentation and diagnosis of inflammatory bowel disease in children", section on 'Stool testing for enteric pathogens'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H849136042">
         <span class="h2">
          Radiographic and endoscopic evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because the treatment goal is typically to achieve mucosal healing (the "treat-to-target" approach (see
         <a class="local">
          'Treatment goals'
         </a>
         above)), endoscopy and colonoscopy with biopsies should be performed 6 to 12 months after initiation of any therapy to determine whether the therapy was successful. Once mucosal healing is achieved, further evaluation is prompted by signs and symptoms of disease activity and may consist of repeat radiographic and/or endoscopic assessment. Increasingly, repeat imaging (with MRI; specifically, magnetic resonance enterography [MRE]) and reassessment with colonoscopy are being performed even in the absence of clinical symptoms because data from trials suggest that clinical remission is not necessarily accompanied by endoscopic remission [
         <a href="#rid9">
          9,10
         </a>
         ]. Decisions about the intensity of endoscopic and radiographic monitoring are based on theoretical long-term advantages of achieving mucosal healing, balanced against the potential short-term costs and burden of the procedures (see
         <a class="local">
          'Treatment goals'
         </a>
         above). In some centers, contrast-enhanced ultrasound is used for follow-up of small bowel CD. This test has the benefit of being less invasive and easier for the patient but provides less information than MRI [
         <a href="#rid11">
          11,12
         </a>
         ]. Indications for and selection among the endoscopic and imaging options are discussed in a separate topic review. (See
         <a class="medical medical_review" href="/z/d/html/5879.html" rel="external">
          "Clinical presentation and diagnosis of inflammatory bowel disease in children", section on 'Diagnostic evaluation'
         </a>
         .)
        </p>
        <p>
         For patients with extensive CD of the colon, we begin surveillance colonoscopy approximately 8 to 10 years after the diagnosis of IBD [
         <a href="#rid13">
          13
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/96979.html" rel="external">
          "Important health maintenance issues for children and adolescents with inflammatory bowel disease", section on 'Surveillance for cancer'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H828643533">
         <span class="h2">
          Systems for scoring disease activity
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          The Pediatric CD Activity Index (PCDAI)
         </strong>
         — Disease activity may be quantified using the PCDAI; this system is primarily used for clinical trials but also may be useful for routine evaluation of hospitalized patients  (
         <a class="graphic graphic_table graphicRef100489" href="/z/d/graphic/100489.html" rel="external">
          table 4
         </a>
         ). The PCDAI permits the calculation of a numerical score ranging from 0 to 100 based upon a child's well-being, degree of abdominal pain, bowel movements, weight gain, linear growth, physical examination, hematocrit, sedimentation rate, and serum albumin [
         <a href="#rid14">
          14,15
         </a>
         ]. A score of 0 to 10 denotes inactive disease, 11 to 30 mild disease activity, and over 30 moderate to severe disease activity [
         <a href="#rid16">
          16
         </a>
         ]. It is validated for children 3.5 to 19 years of age [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Endoscopic scoring systems
         </strong>
         – Endoscopic monitoring of disease activity is increasingly used to assess response to therapy, ideally using a scoring system to quantify the findings. Studies in adults support a standardized method of reporting ileoscopy and colonoscopy, involving the use of the simple endoscopic score for CD (SES-CD). The SES-CD is accurate and easier to use than other endoscopic activity assessments [
         <a href="#rid13">
          13,17
         </a>
         ]. This index has not been formally validated in pediatric patients. A modified version of this scoring system for evaluating upper gastrointestinal findings in children (the UGI SES-CD) has been evaluated in one study in children but is not yet in widespread use [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient self-report systems
         </strong>
         – The US Food and Drug Administration has recommended that patient-reported outcomes (ie, questions answered by the patients themselves rather than their clinicians) be utilized in future drug trials for adult and pediatric IBD [
         <a href="#rid19">
          19,20
         </a>
         ]. For pediatric CD, these include general and disease-specific quality-of-life measures, including PedsQL and the IMPACT-35 quality-of-life scale [
         <a href="#rid21">
          21-23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H365021771">
         <span class="h1">
          SELECTION OF MEDICAL TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following sections summarize our suggestions for treatment in a variety of commonly encountered clinical settings. For each medication, the efficacy and potential risks are discussed in a separate topic review. (See
         <a class="medical medical_review" href="/z/d/html/120380.html" rel="external">
          "Medical therapies for Crohn disease in children and adolescents"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4117071223">
         <span class="h2">
          Ileocolonic disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         For CD affecting the ileum and/or colon, treatment choices depend on disease severity and response  (
         <a class="graphic graphic_algorithm graphicRef64031" href="/z/d/graphic/64031.html" rel="external">
          algorithm 1
         </a>
         ). Disease severity is based on the clinician's global assessment, which is outlined above (see
         <a class="local">
          'Clinical assessment'
         </a>
         above), or on the Pediatric CD Activity Index (PCDAI). (See
         <a class="local">
          'Systems for scoring disease activity'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1799026068">
         <span class="h3">
          Mild
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with mild disease limited to the terminal ileum and/or colon and no complications, we generally make an initial attempt to induce remission using aminosalicylates, with or without antibiotics  (
         <a class="graphic graphic_table graphicRef65046" href="/z/d/graphic/65046.html" rel="external">
          table 1
         </a>
         ). If there is active ileitis, the choice of aminosalicylate should be a timed-release or pH-sensitive release form of
         <a class="drug drug_pediatric" data-topicid="12584" href="/z/d/drug information/12584.html" rel="external">
          mesalamine
         </a>
         (Pentasa or Asacol) and not one of the other aminosalicylates that are released only in the colon. The use of these agents in this population is based on limited data, consisting of clinical experience and open-label observational studies; no randomized clinical trials have exclusively studied the mild disease phenotype. A mild disease course for the first two years after diagnosis appears to be an uncommon phenotype, but when it does occur, most patients continue to have a mild disease course and do not require escalation to immunosuppressive agents [
         <a href="#rid24">
          24
         </a>
         ]. Reasonable alternatives are to induce remission with glucocorticoids (either topical
         <a class="drug drug_pediatric" data-topicid="13096" href="/z/d/drug information/13096.html" rel="external">
          budesonide
         </a>
         [enemas] or systemic
         <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">
          prednisone
         </a>
         , depending on disease location) or with exclusive enteral nutrition (EEN) therapy. Topical glucocorticoids also may be used as adjuncts to other therapies for patients with rectal involvement. (See
         <a class="medical medical_review" href="/z/d/html/120380.html" rel="external">
          "Medical therapies for Crohn disease in children and adolescents", section on 'Aminosalicylates'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/120380.html" rel="external">
          "Medical therapies for Crohn disease in children and adolescents", section on 'Antibiotics'
         </a>
         and
         <a class="local">
          'Exclusive enteral nutrition'
         </a>
         below.)
        </p>
        <p>
         Once remission is induced, the patient is transitioned to maintenance therapy with aminosalicylates alone. Aminosalicylates are less effective but have lower toxicity than immunosuppressive agents. As a result, we generally attempt maintenance with aminosalicylates before considering immunosuppressive therapy for patients with mild disease.
        </p>
        <p>
         If clinical symptoms recur after induction therapy is discontinued, we may attempt re-induction with another course of enteral nutrition or
         <a class="drug drug_pediatric" data-topicid="13096" href="/z/d/drug information/13096.html" rel="external">
          budesonide
         </a>
         . For those who respond, we transition to another maintenance agent, typically an anti-tumor necrosis factor (anti-TNF) agent (
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13077" href="/z/d/drug information/13077.html" rel="external">
          adalimumab
         </a>
         ), a thiopurine (
         <a class="drug drug_pediatric" data-topicid="12582" href="/z/d/drug information/12582.html" rel="external">
          mercaptopurine
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12923" href="/z/d/drug information/12923.html" rel="external">
          azathioprine
         </a>
         ), or, occasionally, subcutaneous
         <a class="drug drug_pediatric" data-topicid="12595" href="/z/d/drug information/12595.html" rel="external">
          methotrexate
         </a>
         . Patients with recurrent flares requiring glucocorticoid treatment (eg, two or more flares in a 12-month period) are likely to benefit from one of these therapies to reduce glucocorticoid use [
         <a href="#rid25">
          25
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/120380.html" rel="external">
          "Medical therapies for Crohn disease in children and adolescents", section on 'Maintenance medications'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3245517568">
         <span class="h3">
          Moderate or severe
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with moderate or severe CD, there is considerable variation in practice for induction therapy. Options for induction therapy include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Early use of an anti-TNF agent, either
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13077" href="/z/d/drug information/13077.html" rel="external">
          adalimumab
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Glucocorticoids
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         EEN
        </p>
        <p>
        </p>
        <p>
         Prior to beginning immunosuppressive treatment, patients should be evaluated for tuberculosis risk factors and tested for latent infection using tuberculin skin testing or interferon-gamma release assay (IGRA). In addition, immunization status should be carefully reviewed and brought up to date, including measurement of titers for measles, hepatitis B virus (HBV), and varicella serologies  (
         <a class="graphic graphic_table graphicRef108934" href="/z/d/graphic/108934.html" rel="external">
          table 5
         </a>
         ) [
         <a href="#rid26">
          26
         </a>
         ]. It is reasonable to take these steps as soon as IBD is diagnosed because many patients will eventually require immunosuppressive treatment [
         <a href="#rid27">
          27
         </a>
         ]. Administration of live viral vaccines warrant special planning because live vaccines are not recommended for immunosuppressed patients. (See
         <a class="medical medical_review" href="/z/d/html/96979.html" rel="external">
          "Important health maintenance issues for children and adolescents with inflammatory bowel disease", section on 'Infection risk'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/96979.html" rel="external">
          "Important health maintenance issues for children and adolescents with inflammatory bowel disease", section on 'Immunizations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H366799894">
         <span class="h4">
          High-risk patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         For selected patients with risk factors for complicated CD (extensive small bowel disease, severe ulcerating colonic disease, growth failure in mid- to late puberty, severe perianal disease, or steroid-unresponsive disease), we suggest use of
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13077" href="/z/d/drug information/13077.html" rel="external">
          adalimumab
         </a>
         soon after diagnosis (within the first two to three months) rather than induction therapy with glucocorticoids followed by an immunomodulator  (
         <a class="graphic graphic_algorithm graphicRef75566" href="/z/d/graphic/75566.html" rel="external">
          algorithm 2
         </a>
         ). Patients with these characteristics have an increased risk of poor disease outcome, and there is moderate evidence to guide patient selection for this approach [
         <a href="#rid1">
          1
         </a>
         ]. Infliximab or adalimumab usually have rapid onset of action and can be used as the initial induction medication or shortly after induction with corticosteroids. Alternatively, it is reasonable to manage these patients by inducing with EEN or glucocorticoids, followed by maintenance therapy with an immunomodulator, based on patient preference or if infliximab or adalimumab are not available  (
         <a class="graphic graphic_algorithm graphicRef64031" href="/z/d/graphic/64031.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
         A beneficial effect for early treatment with
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13077" href="/z/d/drug information/13077.html" rel="external">
          adalimumab
         </a>
         in selected patients was suggested by a large, multicenter observational study in children with newly diagnosed inflammatory (nonpenetrating, nonstricturing) CD, in which early treatment was compared with early treatment with an immunomodulator (eg,
         <a class="drug drug_pediatric" data-topicid="12582" href="/z/d/drug information/12582.html" rel="external">
          mercaptopurine
         </a>
         ) and no immunotherapy [
         <a href="#rid28">
          28
         </a>
         ]. The groups were matched by a "propensity score," which effectively narrowed the comparison to subjects with relatively high risks for complicated disease. After one year, remission was achieved in 85.3 percent of the children treated with an anti-TNF antibody versus 60.3 percent of those treated with an immunomodulator, and 54.4 percent of those managed without immunotherapy. Early treatment with an anti-TNF antibody was also associated with lower use of corticosteroids and a modest improvement in linear growth compared with the other treatment groups.
        </p>
        <p>
         The choice between
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13077" href="/z/d/drug information/13077.html" rel="external">
          adalimumab
         </a>
         depends on clinician and patient preferences, such as a preference for subcutaneous administration (eg, adalimumab) versus infusions (eg, infliximab). Details about the use of infliximab, adalimumab, and other anti-TNF agents, including dosing, efficacy, safety, and decisions about use in combination with other immunosuppressive medications, are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/120380.html" rel="external">
          "Medical therapies for Crohn disease in children and adolescents", section on 'First-line biologic agents'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/120380.html" rel="external">
          "Medical therapies for Crohn disease in children and adolescents", section on 'Anti-TNF monotherapy versus combination therapy with an immunomodulator'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3643515085">
         <span class="h4">
          Standard-risk patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with moderate or severe disease but
         <strong>
          without
         </strong>
         risk factors for complicated disease, as described above, several strategies are used  (
         <a class="graphic graphic_algorithm graphicRef64031" href="/z/d/graphic/64031.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Glucocorticoids or EEN
         </strong>
         – We typically initiate treatment with glucocorticoids to induce remission  (
         <a class="graphic graphic_algorithm graphicRef64031" href="/z/d/graphic/64031.html" rel="external">
          algorithm 1
         </a>
         ). We use oral glucocorticoids for those with moderate disease and intravenous glucocorticoids for more severe disease. Some patients with more severe abdominal symptoms may benefit from a limited course of bowel rest (up to two weeks) while glucocorticoids are initiated, with total parenteral nutrition (TPN) to maintain nutrition [
         <a href="#rid29">
          29,30
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/120380.html" rel="external">
          "Medical therapies for Crohn disease in children and adolescents", section on 'Glucocorticoids'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         EEN is an appropriate alternative to glucocorticoids, especially for patients with growth failure; this approach is frequently used as an induction regimen in the United Kingdom and in parts of Europe and Canada. (See
         <a class="local">
          'Exclusive enteral nutrition'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If remission is successfully induced by glucocorticoids or EEN, patients may be transitioned to another regimen for maintenance treatment, typically an anti-TNF biologic and/or a thiopurine (
         <a class="drug drug_pediatric" data-topicid="12582" href="/z/d/drug information/12582.html" rel="external">
          mercaptopurine
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12923" href="/z/d/drug information/12923.html" rel="external">
          azathioprine
         </a>
         ),
         <a class="drug drug_general" data-topicid="95501" href="/z/d/drug information/95501.html" rel="external">
          vedolizumab
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="126474" href="/z/d/drug information/126474.html" rel="external">
          ustekinumab
         </a>
         (in those who lost response to anti-TNF therapy (see
         <a class="local">
          'Refractory disease'
         </a>
         below)), or subcutaneous
         <a class="drug drug_pediatric" data-topicid="12595" href="/z/d/drug information/12595.html" rel="external">
          methotrexate
         </a>
         . If thiopurine treatment is planned, patients should be evaluated for thiopurine methyltransferase genotype (TPMT genotype) or phenotype (TPMT activity) to determine a safe starting dose. Clinical practice is trending away from selecting thiopurines because of their apparent association with malignancy risk. Use of subcutaneous methotrexate is limited by lower response rates; side effects of nausea, headache, and fatigue; and route of administration [
         <a href="#rid31">
          31
         </a>
         ]. A plain-language summary to guide treatment decisions is outlined in the table  (
         <a class="graphic graphic_table graphicRef107130" href="/z/d/graphic/107130.html" rel="external">
          table 6
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/120380.html" rel="external">
          "Medical therapies for Crohn disease in children and adolescents", section on 'Maintenance medications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anti-TNF biologics
         </strong>
         – Many clinicians, particularly those practicing in North America, choose to bypass one or more of the above steps and go directly to
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13077" href="/z/d/drug information/13077.html" rel="external">
          adalimumab
         </a>
         , or another anti-TNF biologic agent for these standard-risk patients  (
         <a class="graphic graphic_algorithm graphicRef64031" href="/z/d/graphic/64031.html" rel="external">
          algorithm 1
         </a>
         ). The relative risks of these two strategies have not been fully established. Considerations are:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Potential advantages of using anti-TNF agents are the greater efficacy of these biologic agents compared with thiopurines [
         <a href="#rid10">
          10,32
         </a>
         ]. Also, anti-TNF agents probably carry a lower risk for lymphoma than thiopurines, although absolute prevalence of lymphoma is low with either of these drugs as monotherapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Potential disadvantages of anti-TNF agents are their high cost relative to thiopurines and that early use of
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         may lead to loss of response due to development of antibodies to infliximab. Patients on anti-TNF agents have an increased risk for pulmonary opportunistic infections, psoriasis, and neurologic and infusion reactions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         (See
         <a class="medical medical_review" href="/z/d/html/120380.html" rel="external">
          "Medical therapies for Crohn disease in children and adolescents", section on 'Maintenance medications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Aminosalicylates
         </strong>
         – Aminosalicylates may be considered for patients who are strongly opposed to immunosuppression, but it is unclear if these drugs are superior to placebo in preventing relapse. Patients with recurrent flares requiring glucocorticoid treatment (eg, two or more flares in a 12-month period) are likely to benefit from immunosuppressive (immunomodulatory or biologic) therapy to reduce glucocorticoid use [
         <a href="#rid25">
          25
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/120380.html" rel="external">
          "Medical therapies for Crohn disease in children and adolescents", section on 'Aminosalicylates'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H525596916">
         <span class="h3">
          Fistulizing disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         The transmural, inflammatory nature of CD predisposes to the formation of fistulae, a complication that may dominate the clinical picture in some patients. For complicated or refractory fistulizing/penetrating disease,
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13077" href="/z/d/drug information/13077.html" rel="external">
          adalimumab
         </a>
         is the treatment of choice, sometimes initially combined with bowel rest and TPN for severely ill patients [
         <a href="#rid1">
          1
         </a>
         ]. Treatment with infliximab does not appear to increase the risk for abscess formation. (See
         <a class="medical medical_review" href="/z/d/html/120380.html" rel="external">
          "Medical therapies for Crohn disease in children and adolescents", section on 'First-line biologic agents'
         </a>
         .)
        </p>
        <p>
         A thiopurine or
         <a class="drug drug_pediatric" data-topicid="12595" href="/z/d/drug information/12595.html" rel="external">
          methotrexate
         </a>
         also may be helpful for fistulizing disease (as maintenance but not induction therapy). Because these are older drugs, there is less evidence for their efficacy for fistulizing disease than for biologic agents [
         <a href="#rid33">
          33
         </a>
         ]. Antibiotics (eg,
         <a class="drug drug_pediatric" data-topicid="13157" href="/z/d/drug information/13157.html" rel="external">
          ciprofloxacin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12606" href="/z/d/drug information/12606.html" rel="external">
          metronidazole
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          azithromycin
         </a>
         ) are sometimes used for patients with mild or uncomplicated fistulizing disease (especially perianal fistulas), despite limited evidence. Glucocorticoids and aminosalicylates are not beneficial for fistulizing disease. Management of perianal fistulizing disease is discussed below. (See
         <a class="medical medical_review" href="/z/d/html/120380.html" rel="external">
          "Medical therapies for Crohn disease in children and adolescents", section on 'Antibiotics'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16224.html" rel="external">
          "Medical management of moderate to severe Crohn disease in adults", section on 'Fistulizing disease'
         </a>
         and
         <a class="local">
          'Perianal disease'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H21135821">
         <span class="h3">
          Abdominal abscess
         </span>
         <span class="headingEndMark">
          —
         </span>
         Abdominal abscesses (with or without fistulae) should be treated with the combination of percutaneous drainage and systemic antibiotics. Percutaneous drainage promotes healing and should be performed for abscesses larger than 2 cm [
         <a href="#rid33">
          33
         </a>
         ]. Patients should not be fed and are supported with TPN, and the drain should be left in place until the output is low (eg, &lt;10 mL/day).
        </p>
        <p>
         Antibiotics should initially be selected empirically to target both nosocomial and community-acquired organisms. Appropriate intravenous regimens include
         <a class="drug drug_pediatric" data-topicid="13375" href="/z/d/drug information/13375.html" rel="external">
          imipenem
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12708" href="/z/d/drug information/12708.html" rel="external">
          piperacillin-tazobactam
         </a>
         , ticarcillin-clavulanate (where available), or the combination of
         <a class="drug drug_pediatric" data-topicid="13134" href="/z/d/drug information/13134.html" rel="external">
          ceftazidime
         </a>
         with
         <a class="drug drug_pediatric" data-topicid="12606" href="/z/d/drug information/12606.html" rel="external">
          metronidazole
         </a>
         [
         <a href="#rid33">
          33
         </a>
         ]. Once cultures are obtained, the antibiotic spectrum should be narrowed based on sensitivities of cultured organisms.
        </p>
        <p>
         Patients with persistent or recurrent abscesses are candidates for percutaneous drainage, followed by surgical resection of the affected intestinal segment [
         <a href="#rid33">
          33
         </a>
         ]. There is ongoing controversy about whether a patient with an abdominal abscess can be managed by percutaneous drainage followed by biologic therapy or whether all patients with abdominal abscess should proceed to surgery [
         <a href="#rid33">
          33
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/86198.html" rel="external">
          "Surgical management of Crohn disease", section on 'Immunosuppressive or biologic therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2654785142">
         <span class="h3">
          Refractory disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with ongoing symptoms while on the initial maintenance treatment (whether aminosalicylate, immunomodulator, or anti-TNF biologic) should be reevaluated after three to six months. The reevaluation should ideally include endoscopy to permit disease restaging and to provide objective evidence of lack of or loss of response versus other causes of symptoms such as irritable bowel syndrome, as well as consideration given to change of therapy.
        </p>
        <p>
         Approximately 30 percent of children with CD are refractory to or dependent on steroids despite concomitant use of thiopurines (
         <a class="drug drug_pediatric" data-topicid="12582" href="/z/d/drug information/12582.html" rel="external">
          mercaptopurine
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12923" href="/z/d/drug information/12923.html" rel="external">
          azathioprine
         </a>
         ) [
         <a href="#rid34">
          34
         </a>
         ], and a few others are intolerant of thiopurines. In this case, the first-line treatment options are
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13077" href="/z/d/drug information/13077.html" rel="external">
          adalimumab
         </a>
         (
         <a class="graphic graphic_algorithm graphicRef75566" href="/z/d/graphic/75566.html" rel="external">
          algorithm 2
         </a>
         ). Details about the use of infliximab and adalimumab, including dosing, efficacy, safety, and decisions about use in combination with other immunosuppressive medications, are discussed separately. Patients who do not respond to anti-TNF treatment may benefit from dose adjustment of the anti-TNF, reevaluation to see if there is a surgically resectable segment, or change to another treatment. (See
         <a class="medical medical_review" href="/z/d/html/120380.html" rel="external">
          "Medical therapies for Crohn disease in children and adolescents", section on 'First-line biologic agents'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/120380.html" rel="external">
          "Medical therapies for Crohn disease in children and adolescents", section on 'Anti-TNF monotherapy versus combination therapy with an immunomodulator'
         </a>
         .)
        </p>
        <p>
         Second-line options for patients who do not respond to immunomodulator and anti-TNF treatment include
         <a class="drug drug_pediatric" data-topicid="126474" href="/z/d/drug information/126474.html" rel="external">
          ustekinumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="95501" href="/z/d/drug information/95501.html" rel="external">
          vedolizumab
         </a>
         , or, occasionally, surgical resection of a discrete diseased segment of the bowel. Vedolizumab and ustekinumab are being studied in children and may transition to first-line biologic treatments because of their better safety profile. (See
         <a class="local">
          'Surgery'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/120380.html" rel="external">
          "Medical therapies for Crohn disease in children and adolescents", section on 'Second-line biologic agents'
         </a>
         .)
        </p>
        <p>
         Before beginning immunosuppressive treatment, patients should be evaluated for latent tuberculosis infection and immunizations brought up to date, as discussed above. (See
         <a class="local">
          'Moderate or severe'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3781895591">
         <span class="h2">
          Other disease locations
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to the above general guidelines for medication choice by disease severity and response to treatment, some medication choices are influenced by disease location.
        </p>
        <p class="headingAnchor" id="H3107759597">
         <span class="h3">
          Oral lesions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Topical
         <a class="drug drug_pediatric" data-topicid="12723" href="/z/d/drug information/12723.html" rel="external">
          prednisolone
         </a>
         syrup may be helpful. For lesions on the lips, consider 0.1%
         <a class="drug drug_pediatric" data-topicid="12858" href="/z/d/drug information/12858.html" rel="external">
          triamcinolone
         </a>
         applied to the lips. Evaluate for systemic disease and treat accordingly.
        </p>
        <p class="headingAnchor" id="H2192258861">
         <span class="h3">
          Gastroduodenal disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment is induced with glucocorticoids for other enteric disease locations. However, because aminosalicylates are ineffective in the stomach, patients with medically significant gastroduodenal disease should be treated with
         <a class="drug drug_pediatric" data-topicid="12582" href="/z/d/drug information/12582.html" rel="external">
          mercaptopurine
         </a>
         /
         <a class="drug drug_pediatric" data-topicid="12923" href="/z/d/drug information/12923.html" rel="external">
          azathioprine
         </a>
         , subcutaneous
         <a class="drug drug_pediatric" data-topicid="12595" href="/z/d/drug information/12595.html" rel="external">
          methotrexate
         </a>
         , or anti-TNF biologic therapy for maintenance therapy. Acid blockade for gastritis or esophagitis with proton pump inhibitors (eg,
         <a class="drug drug_pediatric" data-topicid="12658" href="/z/d/drug information/12658.html" rel="external">
          omeprazole
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12543" href="/z/d/drug information/12543.html" rel="external">
          lansoprazole
         </a>
         ) may be helpful.
        </p>
        <p class="headingAnchor" id="H491448991">
         <span class="h3">
          Active ileitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         If disease appears to involve the ileum, treatment is similar to that for ileocolonic disease as outlined above and may include glucocorticoids, aminosalicylates, immunomodulators, or anti-TNF antibodies. For these patients, the choice of aminosalicylate should be a timed-release or pH-sensitive release form of
         <a class="drug drug_pediatric" data-topicid="12584" href="/z/d/drug information/12584.html" rel="external">
          mesalamine
         </a>
         (Pentasa or Asacol) and not one of the other aminosalicylates that are released only in the colon. Similarly, if
         <a class="drug drug_pediatric" data-topicid="13096" href="/z/d/drug information/13096.html" rel="external">
          budesonide
         </a>
         is selected, the formulation should be enteric coated (eg, Entocort) to distribute the drug to the ileum and cecum. Patients whose disease is limited to the ileum and does not respond to medical treatment are good surgical candidates. (See
         <a class="medical medical_review" href="/z/d/html/120380.html" rel="external">
          "Medical therapies for Crohn disease in children and adolescents", section on 'Aminosalicylates'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/120380.html" rel="external">
          "Medical therapies for Crohn disease in children and adolescents", section on 'Budesonide'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3013082199">
         <span class="h3">
          Isolated colonic Crohn disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Colonic CD is generally treated with corticosteroid or nutrition induction, transitioning to immunomodulators or biologics for maintenance, similar to management of ileocolonic CD, as described above (see
         <a class="local">
          'Ileocolonic disease'
         </a>
         above). Increasingly in the United States, anti-TNF therapy is the primary medical modality utilized. Some clinicians bypass corticosteroids and utilize anti-TNF for induction and maintenance. In very mild cases of Crohn colitis (eg, very mild inflammation with a few granulomas seen on biopsy), an aminosalicylate such as
         <a class="drug drug_pediatric" data-topicid="12817" href="/z/d/drug information/12817.html" rel="external">
          sulfasalazine
         </a>
         may be attempted, but the patient needs to be followed closely to make sure the disease does not progress. (See
         <a class="medical medical_review" href="/z/d/html/120380.html" rel="external">
          "Medical therapies for Crohn disease in children and adolescents", section on 'Second-line biologic agents'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3571061559">
         <span class="h3">
          Proctitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with prominent rectal CD, rectally administered glucocorticoids or aminosalicylate preparations may be useful as adjunct therapy. Options include
         <a class="drug drug_pediatric" data-topicid="12584" href="/z/d/drug information/12584.html" rel="external">
          mesalamine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13361" href="/z/d/drug information/13361.html" rel="external">
          hydrocortisone
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="13096" href="/z/d/drug information/13096.html" rel="external">
          budesonide
         </a>
         formulated as an enema, foam, or suppository.
        </p>
        <p class="headingAnchor" id="H837580567">
         <span class="h3">
          Perianal disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         A detailed assessment of the perianal disease is valuable to determine the appropriate therapy and monitor the clinical response [
         <a href="#rid35">
          35
         </a>
         ]. An examination under anesthesia, ultrasonography, and/or pelvic magnetic resonance imaging (MRI) may be necessary for a full evaluation.
        </p>
        <p>
         Any perianal abscesses should be drained surgically if needed, followed by antibiotics. For perianal fistulas, antibiotics (
         <a class="drug drug_pediatric" data-topicid="12606" href="/z/d/drug information/12606.html" rel="external">
          metronidazole
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13157" href="/z/d/drug information/13157.html" rel="external">
          ciprofloxacin
         </a>
         ) are generally used as initial therapy, although the evidence supporting their efficacy is limited [
         <a href="#rid35">
          35,36
         </a>
         ].
         <a class="drug drug_pediatric" data-topicid="12582" href="/z/d/drug information/12582.html" rel="external">
          Mercaptopurine
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12923" href="/z/d/drug information/12923.html" rel="external">
          azathioprine
         </a>
         should be added if the perineum does not heal. For complicated or refractory perianal disease,
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         or some other anti-TNF agent is the treatment of choice and may be particularly valuable for patients with enterocutaneous fistulas. Glucocorticoids should generally be avoided for patients with clinically significant fistulizing disease since they appear to be associated with worse outcomes for this group of patients [
         <a href="#rid35">
          35,37
         </a>
         ]. Perianal setons are commonly utilized to promote drainage, prevent abscess recurrence, and provide pain relief. However, they will keep a fistulous tract open indefinitely until the seton is removed.
        </p>
        <p>
         The assessment and management of perianal disease is discussed in a consensus statement from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) [
         <a href="#rid35">
          35
         </a>
         ] and in a separate topic review. (See
         <a class="medical medical_review" href="/z/d/html/4082.html" rel="external">
          "Perianal Crohn disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h1">
          NUTRITIONAL THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nutritional therapy has three distinct applications in the treatment of CD:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Exclusive enteral nutrition (EEN) – Providing all nutritional needs through a liquid formula (EEN or primary nutritional therapy) can promote mucosal healing in a patient with active disease and suppress intestinal inflammation, possibly by altering the gut microflora [
         <a href="#rid38">
          38-40
         </a>
         ]. In this context, nutritional therapy is used as an alternative or supplement to antiinflammatory medications. Nutritional therapy may be particularly useful in motivated children and families who wish to avoid corticosteroids. (See
         <a class="local">
          'Exclusive enteral nutrition'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Supplemental enteral nutrition – Enteral nutrition can also be used as a supplement to increase energy and nutrient intake and promote growth in a patient with growth failure while the patient continues to take food orally. Supplemental enteral nutrition may also maintain remission by suppressing intestinal inflammation. (See
         <a class="medical medical_review" href="/z/d/html/5893.html" rel="external">
          "Growth failure and pubertal delay in children with inflammatory bowel disease"
         </a>
         and
         <a class="local">
          'Supplemental enteral nutrition'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Micronutrient deficiencies – Children with CD are at risk for micronutrient deficiencies due to inadequate food intake and malabsorption, including deficiencies of iron, vitamin B12, and zinc. Optimal care includes routine monitoring for these deficiencies and replacement as needed  (
         <a class="graphic graphic_table graphicRef66288" href="/z/d/graphic/66288.html" rel="external">
          table 3
         </a>
         ). Assurance of adequate intake of calcium and vitamin D are particularly important to minimize risks of osteopenia and osteoporosis. (See
         <a class="medical medical_review" href="/z/d/html/5887.html" rel="external">
          "Vitamin and mineral deficiencies in inflammatory bowel disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/96979.html" rel="external">
          "Important health maintenance issues for children and adolescents with inflammatory bowel disease", section on 'Bone mineral density'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1627203142">
         <span class="h2">
          Exclusive enteral nutrition
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Technique
         </strong>
         – EEN requires that the patient stop eating and receive all dietary energy from formula (taken by mouth, nasogastric tube, or gastrostomy) for 8 to 12 weeks. In most centers, the duration of a course of EEN is six to eight weeks. A daily volume of formula is calculated based on estimated energy requirements and adjusted based on serial measurements of weight and height. The method and evidence base for EEN are reviewed in guidelines from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) [
         <a href="#rid41">
          41
         </a>
         ], the British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) [
         <a href="#rid42">
          42
         </a>
         ], and the European Crohn's and Colitis Organisation (ECCO) [
         <a href="#rid1">
          1
         </a>
         ]. The NASPGHAN guideline includes
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.naspghan.org%2Ffiles%2Fdocuments%2Fpdfs%2Fposition-papers%2FUse_of_Enteral_Nutrition_for_the_Control_of.29%255b1%255d.pdf&amp;token=TzB9B8JLcRYCIF9zBGog579NX7l3FEtqc3obgVu0d12MF2MdFm%2F0BPwsMBTX3XETsVHu7yrKiRn%2BLJCGMUKJ2af4s6lF795%2BBpKjG56mEdrP2J7a3XR1pXsZw7D%2BFr1i26b3mL73s2P1J1EquNVMhg%3D%3D&amp;TOPIC_ID=5866" target="_blank">
          practical considerations for implementation of EEN
         </a>
         , including calculation of energy needs and methods of nasogastric tube feeding [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – EEN appears to suppress inflammation and promote mucosal healing [
         <a href="#rid1">
          1,41-46
         </a>
         ]. Moreover, small randomized trials suggest that EEN improves growth as compared with glucocorticoids [
         <a href="#rid47">
          47-49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         EEN appears to be useful for inducing remission but may be less effective than glucocorticoids. Treatment failures in trials of EEN therapy may be partly explained by patient withdrawal from therapy. In the largest meta-analysis of randomized trials, 83 percent of children treated with EEN achieved remission compared with 61 percent of those treated with glucocorticoids, a difference that was not statistically significant (relative risk [RR] 1.35, 95% CI 0.92-1.97) [
         <a href="#rid50">
          50
         </a>
         ]. In adults, EEN was less likely to achieve remission than glucocorticoids (45 percent versus 73 percent, RR 0.65, 95% CI 0.52-0.82). Subgroup analyses showed no significant differences in effectiveness between formulas of different protein composition (elemental versus polymeric). These findings are consistent with an earlier meta-analysis of eight studies conducted prior to 1995, in which the remission rate ranged from 50 to 80 percent after four weeks of EEN [
         <a href="#rid51">
          51
         </a>
         ]. One of the included studies found that EEN induced mucosal healing more often than glucocorticoids, while the two treatments were equally effective in inducing remission [
         <a href="#rid43">
          43
         </a>
         ]. One report suggests that EEN may be less effective in CD that is limited to the colon as compared with ileocolic CD [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The effects of EEN on quality of life and psychological well-being are not well studied. One study found that treatment with EEN was associated with improvements on a standardized measure of quality of life and that this was closely correlated with disease activity [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient selection
         </strong>
         – The option of treatment with EEN should be routinely discussed as an alternative to glucocorticoids for induction of remission in children with CD. This is consistent with North American guidelines [
         <a href="#rid27">
          27,41
         </a>
         ]. European guidelines encourage EEN in preference to glucocorticoids [
         <a href="#rid1">
          1,27,41,42
         </a>
         ]. An important determinant of the decision is the family's and patient's willingness to commit to the EEN regimen, which involves drinking only formula and eating no food for 8 to 12 weeks. Adherence to the treatment protocol is essential for treatment success, and the family and patient should be informed that response to treatment may be gradual. EEN may be particularly appropriate for patients with growth failure and/or those who are steroid-dependent [
         <a href="#rid25">
          25
         </a>
         ]. This suggestion is based on knowledge of the established adverse effects of glucocorticoids, particularly on bone density, and on the evidence that EEN is moderately effective for inducing remission and mucosal healing. For patients with severe disease, EEN might be used in combination with other medical treatments for induction of remission.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         EEN is used far less often than glucocorticoids in the United States for treatment of CD. Providers who rarely use EEN generally cite concerns about adherence due to the limited palatability of most formulas and the desire of most North American children to avoid use of a nasogastric tube [
         <a href="#rid54">
          54
         </a>
         ]. EEN is used somewhat more frequently in Canada and much more frequently in Western Europe compared with the United States [
         <a href="#rid1">
          1,42,54-56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Follow-up
         </strong>
         – Little evidence is available to guide maintenance treatment for children in whom EEN successfully induces remission. Options include transition to maintenance medical therapy (eg, 5-aminosalicylic acid or
         <a class="drug drug_pediatric" data-topicid="12582" href="/z/d/drug information/12582.html" rel="external">
          mercaptopurine
         </a>
         ) and/or tapering to partial enteral nutrition (PEN). In one case series, 28 children were transitioned to nocturnal enteral feeds and resumed eating by mouth during the day [
         <a href="#rid57">
          57
         </a>
         ]. These children were less likely to relapse during the subsequent 12 months as compared with a group of children who opted not to use nocturnal feedings (43 percent versus 79 percent relapse, p&lt;0.02). One older study examined intermittent four-week courses of EEN every four months over a year in eight patients with CD and growth failure and found significantly higher weight and height gains, lower disease activity, and decreased
         <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">
          prednisone
         </a>
         use compared with age-matched controls receiving standard medical therapy [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H451374820">
         <span class="h2">
          Partial enteral nutrition with specific exclusion diet
         </span>
         <span class="headingEndMark">
          —
         </span>
         One study suggests that the combination of partial enteral nutrition (PEN) with a specific whole foods-based exclusion diet (CD exclusion diet [CDED]) is more easily accepted by patients than EEN and is at least as effective in inducing remission. In a randomized multinational trial of 74 children with CD, children were treated with 12 weeks of either PEN plus CDED (two six-week phases), or EEN for six weeks transitioning to PEN plus a free diet [
         <a href="#rid59">
          59
         </a>
         ]. Those treated with PEN plus the CDED were more likely to complete six weeks of therapy (98 versus 74 percent) and had similar rates of corticosteroid-free remission (80 versus 74 percent). Since this reflects an intention to treat analysis, the performance of the PEN plus the CDED is likely related to better acceptance with fewer dropouts from that group compared with EEN. The CDED used in this study consists of fruits, vegetables, and selected grains and limits exposure to other foods and food additives purported to induce intestinal dysbiosis (including animal fats, dairy, and gluten) [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h2">
          Supplemental enteral nutrition
         </span>
         <span class="headingEndMark">
          —
         </span>
         Enteral nutrition also has been used as a supplement to a regular diet to maintain remission. Although supplemental therapy is less effective than EEN in inducing remission [
         <a href="#rid44">
          44
         </a>
         ], limited data suggest that it can be helpful in maintaining remission [
         <a href="#rid1">
          1,57,61,62
         </a>
         ]. However, the efficacy of this approach has not been established, and many children are unwilling to continue enteral nutrition long term.
        </p>
        <p>
         Supplemental enteral nutrition also is used to enhance linear growth and nutritional status in children with growth failure. The indications and implementation of this approach are discussed in a separate topic review. (See
         <a class="medical medical_review" href="/z/d/html/5893.html" rel="external">
          "Growth failure and pubertal delay in children with inflammatory bowel disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H28">
         <span class="h2">
          Other dietary changes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although epidemiologic and biologic research suggests a possible role for dietary factors in the pathogenesis of inflammatory bowel disease (IBD) [
         <a href="#rid63">
          63
         </a>
         ], there is no good evidence for specific dietary regimens other than to eat a healthy, diverse diet. A study in adults with CD compared the specific carbohydrate diet to the Mediterranean diet and found comparable remission rates [
         <a href="#rid64">
          64
         </a>
         ]. Therefore, it is reasonable to recommend the Mediterranean diet to patients who want to use a dietary approach as an adjunct to their medical regimen, especially since the Mediterranean diet is beneficial for heart health and may be easier to comply with than the specific carbohydrate diet.
        </p>
        <p>
         The recommendation of a healthy diverse diet is supported by the International Organization for the Study of IBD, which advises patients with IBD to consume a balanced diet composed of carbohydrates, fats, and protein and to limit intake of processed food (eg, sulfites) and artificial sweeteners while avoiding trans fatty acids [
         <a href="#rid65">
          65
         </a>
         ]. These recommendations were based on low- or very low-quality evidence. (See
         <a class="medical medical_review" href="/z/d/html/13924.html" rel="external">
          "Nutrition and dietary management for adults with inflammatory bowel disease"
         </a>
         .)
        </p>
        <p>
         In particular,
         <strong>
          none of the following
         </strong>
         dietary approaches has been shown to be beneficial in maintaining remission:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fat, fiber, and carbohydrates – Observational evidence in humans and experimental evidence in animals suggest that dietary fats and carbohydrates may affect intestinal inflammation [
         <a href="#rid63">
          63
         </a>
         ]. Soluble fiber is fermented into short-chain fatty acids in the colon, which in turn are thought to reduce colonic inflammation. However, the same fermentation process may produce gas and diarrhea, causing increased symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Diets with variable fiber content and carbohydrate composition have been studied in single-blind, randomized trials in adults. Neither diets low in sugar and increased in fiber content [
         <a href="#rid66">
          66,67
         </a>
         ] nor diets with reduced fiber content ("low-residue") altered the clinical course of the subjects as compared with a control group [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         There is insufficient evidence to recommend restriction of wheat and gluten [
         <a href="#rid65">
          65
         </a>
         ]. Gluten-related symptoms reported by many patients may be related to co-ingestion of other fermentable carbohydrates (FODMAPs).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         There is insufficient evidence to recommend restriction of meats or poultry [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Carrageenan and emulsifiers – Limited evidence from animal models and a very small randomized trial suggest that carrageenan can exacerbate inflammation [
         <a href="#rid69">
          69
         </a>
         ]. Animal models also support this possibility for
         <a class="drug drug_general" data-topicid="8844" href="/z/d/drug information/8844.html" rel="external">
          carboxymethylcellulose
         </a>
         or polysorbate 80 [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fish oil – Fish oil and other sources of omega-3 (n-3) fatty acids have antiinflammatory effects in animal models of IBD [
         <a href="#rid70">
          70
         </a>
         ]. However, there is insufficient clinical evidence to draw conclusions about the effects of n-3 fatty acids on the clinical outcomes of CD, based on two systematic reviews of the available literature [
         <a href="#rid71">
          71,72
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5887.html" rel="external">
          "Vitamin and mineral deficiencies in inflammatory bowel disease", section on 'Answers to common clinical questions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other elimination diets – Small observational studies with methodologic flaws suggest that the "specific carbohydrate diet" (which excludes refined sugars, dairy products, and complex carbohydrates), either as primary or adjunct therapy, might be associated with improvement in Pediatric CD Activity Index (PCDAI), serum and stool inflammatory markers, and/or mucosal healing [
         <a href="#rid73">
          73,74
         </a>
         ]. In all cases of dietary therapy, counseling by a registered dietician is advised to make sure that the patient is receiving adequate calories and micronutrients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There is better evidence for the specific exclusion diet (CDED) used in conjunction with partial enteral nutrition to induce remission, as discussed above. (See
         <a class="local">
          'Partial enteral nutrition with specific exclusion diet'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         A few other dietary changes may be appropriate in specific clinical situations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lactose intolerance – Lactose intolerance is more prevalent in patients with CD, particularly those with small bowel disease [
         <a href="#rid75">
          75
         </a>
         ]. These individuals, like other patients with lactose intolerance, may get symptomatic relief from reducing dietary lactose. Thus, for patients with symptoms consistent with lactose intolerance, a trial of a lactose-reduced diet is reasonable. In this case, care should be taken to ensure that adequate dietary calcium and vitamin D are provided.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Strictures – For other patients with CD and strictures, a low-residue diet may be an appropriate step to avoid bowel obstruction. However, it should be recognized that such dietary changes are unlikely to be relevant, except in unusual cases where a stricture is nearly obstructive, and these patients are likely to need other intervention to avoid this complication [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Micronutrient deficiencies – Evaluation and management of vitamin and mineral deficiencies in patients with CD are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5887.html" rel="external">
          "Vitamin and mineral deficiencies in inflammatory bowel disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2610295290">
         <span class="h1">
          SURGERY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Perioperative considerations
         </strong>
         – Hospitalized children and adolescents with inflammatory bowel disease (IBD) are at increased risk for thromboembolism. Though less common than in adults with IBD, thromboembolic (TE) events in children with IBD seem to occur during active disease, with risk factors including previous thromboembolism, major surgery, presence of a central venous catheter, older age, use of parenteral nutrition, and an identified hypercoagulable condition. Routine thromboprophylaxis (anticoagulation) for hospitalized children with IBD remains controversial but should be seriously considered for those with potential risk factors for TE. (See
         <a class="medical medical_review" href="/z/d/html/5865.html" rel="external">
          "Clinical manifestations and complications of inflammatory bowel disease in children and adolescents", section on 'Venous thromboembolism'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Nutrition support (enteral and/or parenteral) should be considered in any IBD patient about to undergo surgery, especially if the patient is malnourished. Preoperative supplemental nutrition reduces postoperative complications, with a trend toward parenteral nutrition being superior to enteral nutrition [
         <a href="#rid77">
          77
         </a>
         ]. (See
         <a class="local">
          'Supplemental enteral nutrition'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications and efficacy
         </strong>
         – Surgery in CD is reserved primarily for patients who do not respond to medications or who develop complications (abscess, fistula, perforation, hemorrhage, obstruction, or stricture) that can only be treated surgically.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A review of surgery in pediatric patients with CD estimated that 3.4 to 7.9 percent will undergo surgery within one year of diagnosis, 13.8 to 47.2 percent by five years, and 28 to 34.5 percent by 10 years [
         <a href="#rid78">
          78
         </a>
         ]. Thus, although treatment of CD primarily is medical, many patients will require surgery at some point during their clinical course (see
         <a class="medical medical_review" href="/z/d/html/86198.html" rel="external">
          "Surgical management of Crohn disease"
         </a>
         ). Risk factors for initial surgery are highest in subjects with complicated disease behavior (stricturing and penetrating disease), anti-
         <em>
          Saccharomyces
         </em>
         <em>
          cerevisiae
         </em>
         antibody (ASCA) positivity, hypoalbuminemia, leukocytosis (at diagnosis), and poor growth [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Surgery can be particularly effective in patients with a limited region of disease (eg, terminal ileal or ileocecal disease). The type of surgery depends on the location and disease of the individual patient. The most common type of surgery is ileal resection with partial colectomy and reanastomosis of the remaining healthy colon to the healthy ileum [
         <a href="#rid79">
          79-82
         </a>
         ]. Less common surgeries include subtotal or total colectomy with permanent ileostomy, segmental removal of colon with reanastomosis, strictureplasty, or isolated small bowel resection. The benefits of surgery include rapid improvement in an ill patient and catch-up of growth and puberty in a child or adolescent [
         <a href="#rid83">
          83,84
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Postoperative complications, including infections, probably are not increased in patients treated with immunomodulators just prior to surgery [
         <a href="#rid85">
          85-87
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/86198.html" rel="external">
          "Surgical management of Crohn disease", section on 'Immunosuppressive or biologic therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Extent of resection
         </strong>
         – Surgery usually involves laparoscopic resection of the diseased bowel segment and primary end-to-end anastomosis. In some patients with multiple small bowel strictures, strictureplasty (widening of the strictured area in a manner similar to pyloroplasty) may reduce the need for bowel resection. Recurrence rates with strictureplasty and resection are similar [
         <a href="#rid88">
          88-90
         </a>
         ]. In patients with extensive Crohn colitis that is not responsive to medical therapy, full colonic resection and end-ileostomy may be unavoidable.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The aim of surgery is to resect as little bowel as possible since CD recurs in approximately 40 to 50 percent of patients within two to five years and approximately 75 percent of patients with 10 years, and approximately 20 percent of patients will require a second surgery within 10 years postoperatively [
         <a href="#rid81">
          81,91
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Postoperative recurrence
         </strong>
         – After surgery, clinical recurrence rates range from 20 to 37 percent at one year and from 34 to 86 percent at three years [
         <a href="#rid92">
          92-94
         </a>
         ]. Endoscopic recurrence precedes the return of clinical symptoms [
         <a href="#rid92">
          92,95
         </a>
         ]. The severity of endoscopic lesions can predict the likelihood of recurrent disease and increased risk of future surgery more than clinical symptoms [
         <a href="#rid96">
          96
         </a>
         ]. For these reasons, endoscopic surveillance of the anastomotic area 6 to 12 months after surgery is recommended to identify a preclinical endoscopic recurrence and allow for earlier treatment modification [
         <a href="#rid1">
          1,97
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Risk factors for earlier postoperative recurrence include diffuse (ileocolonic) rather than focal disease, complicated disease [
         <a href="#rid92">
          92,98,99
         </a>
         ], and younger age at surgery [
         <a href="#rid94">
          94
         </a>
         ]. Early initiation of medical treatment is recommended to prevent postoperative recurrence of CD [
         <a href="#rid1">
          1
         </a>
         ]. Based on adult studies, postoperative medical treatment was associated with better outcomes compared with delaying treatment until after endoscopic inflammation has already developed [
         <a href="#rid100">
          100,101
         </a>
         ]. The treatment target is endoscopic and histologic remission, which are associated with better long-term outcomes compared with measures of clinical symptoms [
         <a href="#rid102">
          102
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A systematic review of studies in adults found that anti-tumor necrosis factor (anti-TNF) agents are the most effective medications at preventing postoperative endoscopic recurrence and suggested that these medications can be started as soon as four weeks after surgery [
         <a href="#rid103">
          103
         </a>
         ]. Thiopurines also have a role in decreasing postoperative recurrence, but their use must be weighed with the small increased risk of hepatosplenic lymphoma [
         <a href="#rid104">
          104
         </a>
         ].
         <a class="drug drug_pediatric" data-topicid="12595" href="/z/d/drug information/12595.html" rel="external">
          Methotrexate
         </a>
         is associated with a lower risk of lymphoma, but there is little evidence to show that methotrexate monotherapy is effective to prevent postoperative recurrence [
         <a href="#rid78">
          78
         </a>
         ]. Aminosalicylates and antibiotics have minimal benefit in reducing the postoperative recurrence rate (from 40 percent untreated to approximately 30 percent if treated with
         <a class="drug drug_pediatric" data-topicid="12584" href="/z/d/drug information/12584.html" rel="external">
          mesalamine
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12606" href="/z/d/drug information/12606.html" rel="external">
          metronidazole
         </a>
         ) [
         <a href="#rid78">
          78,103,105
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4084.html" rel="external">
          "Management of Crohn disease after surgical resection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21769383">
         <span class="h1">
          IMPORTANT HEALTH MAINTENANCE ISSUES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Comprehensive health care for children and adolescents with CD requires special considerations for each of the following health maintenance issues:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Monitoring nutritional status
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bone health
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infection risk
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immunizations
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Eye examinations
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Psychological issues
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Transition to adult health care
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cancer surveillance
        </p>
        <p>
        </p>
        <p>
         Each of these issues is addressed in a separate topic review. (See
         <a class="medical medical_review" href="/z/d/html/96979.html" rel="external">
          "Important health maintenance issues for children and adolescents with inflammatory bowel disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1562521634">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113229.html" rel="external">
          "Society guideline links: Inflammatory bowel disease in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3346265872">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/86454.html" rel="external">
          "Patient education: Crohn disease in children (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/2004.html" rel="external">
          "Patient education: Crohn disease (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8241845">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Assessment and monitoring of disease severity
         </strong>
         – Treatment decisions for patients with Crohn disease (CD) require careful assessment and monitoring of disease location and activity. This includes serial clinical assessments of symptoms and supporting laboratory data, ideally quantified using the Pediatric CD Activity Index (PCDAI)  (
         <a class="graphic graphic_table graphicRef100489" href="/z/d/graphic/100489.html" rel="external">
          table 4
         </a>
         ). Objective assessments, including follow-up magnetic resonance imaging (MRI), upper endoscopy with biopsies, and colonoscopy with biopsies, are increasingly used to monitor disease progression and guide treatment decisions; this is known as a treat-to-target approach. (See
         <a class="local">
          'Assessment of disease activity'
         </a>
         above and
         <a class="local">
          'Treatment goals'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment for mild ileocolonic disease
         </strong>
         – For patients with mild disease of the ileum and/or colon, we suggest an initial attempt to induce remission using aminosalicylates, with or without antibiotics, rather than initial treatment with glucocorticoids (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Aminosalicylates may reduce symptoms in mild cases. However, they are generally ineffective at inducing mucosal healing for many cases of CD. Therefore, close follow-up is needed and, if inflammation persists, use of an immunomodulator or biologic may be needed. (See
         <a class="local">
          'Mild'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment for moderate or severe ileocolonic disease
         </strong>
         – For patients with moderate or severe disease of the ileum and/or colon, a variety of treatments are available  (
         <a class="graphic graphic_table graphicRef65046" href="/z/d/graphic/65046.html" rel="external">
          table 1
         </a>
         ) and there is considerable variation in practice. The choice of drugs typically depends on disease severity and response  (
         <a class="graphic graphic_algorithm graphicRef64031" href="/z/d/graphic/64031.html" rel="external">
          algorithm 1
         </a>
         ). Treatment decisions also depend upon the values and preferences of the patient and family. A plain-language summary to guide treatment decisions is outlined in the table  (
         <a class="graphic graphic_table graphicRef107130" href="/z/d/graphic/107130.html" rel="external">
          table 6
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with risk factors for complicated disease (eg, those with extensive small bowel disease, severe ulcerating colonic disease, growth failure in mid- to late puberty, severe perianal disease, or steroid-unresponsive disease), we suggest early treatment with
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13077" href="/z/d/drug information/13077.html" rel="external">
          adalimumab
         </a>
         rather than induction therapy with glucocorticoids (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). A combination of glucocorticoids with infliximab or adalimumab also may be used for the induction therapy. (See
         <a class="local">
          'High-risk patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with no risk factors for complicated disease, we suggest induction of remission with either glucocorticoids or exclusive enteral nutrition (EEN; either polymeric or elemental formulas) rather than aminosalicylates or anti-tumor necrosis factor (anti-TNF) agents (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The choice between glucocorticoids and EEN depends primarily on patient preference and whether the clinician has experience with this therapy. Use of an anti-TNF agent is a reasonable alternative; the choice depends in part on the intended maintenance regimen and cost considerations. (See
         <a class="local">
          'Standard-risk patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         EEN should be routinely offered as an alternative or adjunct to glucocorticoids or anti-TNF agents for induction of remission in children with CD. EEN may be particularly appropriate for patients with growth failure and/or those who are steroid-dependent. EEN involves drinking only formula and eating no food for 8 to 12 weeks. This approach is moderately effective for inducing remission and mucosal healing and helps to avoid the established adverse effects of glucocorticoids, particularly on bone density. An important determinant of the decision is the family's and patient's willingness to commit to the EEN regimen since this is essential for adherence and treatment success. Preliminary studies suggest that partial enteral nutrition (PEN) with a specific exclusion diet may be as effective and better accepted by patients than EEN. (See
         <a class="local">
          'Exclusive enteral nutrition'
         </a>
         above and
         <a class="local">
          'Partial enteral nutrition with specific exclusion diet'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If patients treated with EEN or glucocorticoids respond to induction therapy, we suggest transitioning to maintenance therapy with a thiopurine (
         <a class="drug drug_pediatric" data-topicid="12582" href="/z/d/drug information/12582.html" rel="external">
          mercaptopurine
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12923" href="/z/d/drug information/12923.html" rel="external">
          azathioprine
         </a>
         ) or subcutaneous
         <a class="drug drug_pediatric" data-topicid="12595" href="/z/d/drug information/12595.html" rel="external">
          methotrexate
         </a>
         rather than aminosalicylates or multiple courses of glucocorticoids (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Before beginning treatment with a thiopurine, patients should be evaluated for the thiopurine methyltransferase genotype (TPMT genotype) or phenotype (TPMT activity) to determine a safe starting dose. Patients treated with these drugs require close monitoring during therapy. Patients who were induced with an anti-TNF agent typically continue on that agent for maintenance. However, the benefits and risks of anti-TNF agents compared with other maintenance agents (thiopurines or methotrexate) are unclear and require further study. (See
         <a class="local">
          'Standard-risk patients'
         </a>
         above and
         <a class="local">
          'Overview of treatment decisions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Refractory ileocolonic disease
         </strong>
         – For patients with ileocolonic disease that is refractory to or dependent on glucocorticoids despite maintenance treatment with thiopurines or
         <a class="drug drug_pediatric" data-topicid="12595" href="/z/d/drug information/12595.html" rel="external">
          methotrexate
         </a>
         , treatment may be advanced by adding
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13077" href="/z/d/drug information/13077.html" rel="external">
          adalimumab
         </a>
         , or another biologic agent (eg,
         <a class="drug drug_general" data-topicid="95501" href="/z/d/drug information/95501.html" rel="external">
          vedolizumab
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="126474" href="/z/d/drug information/126474.html" rel="external">
          ustekinumab
         </a>
         ), with or without concomitant thiopurine or methotrexate. Surgery may be helpful for patients with disease in a discrete segment of the bowel  (
         <a class="graphic graphic_algorithm graphicRef75566" href="/z/d/graphic/75566.html" rel="external">
          algorithm 2
         </a>
         ). (See
         <a class="local">
          'Refractory disease'
         </a>
         above and
         <a class="local">
          'Surgery'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other disease locations
         </strong>
         – Patients with oral lesions, perianal disease, or proctitis may benefit from other treatment strategies. (See
         <a class="local">
          'Other disease locations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Considerations for specific therapies
         </strong>
         – Details about the main medical therapies used for CD are discussed in a separate topic review (see
         <a class="medical medical_review" href="/z/d/html/120380.html" rel="external">
          "Medical therapies for Crohn disease in children and adolescents"
         </a>
         ). Additional considerations include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Immunosuppressive therapy
         </strong>
         – Before beginning treatment with immunosuppressing medications (especially
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         and other anti-TNF antibodies), patients should be evaluated for tuberculosis risk factors and tested for latent infection using tuberculin skin testing or interferon-gamma release assay (IGRA). In addition, immunization status should be carefully reviewed and brought up to date, including measurement of titers for measles and hepatitis B virus (HBV) serologies and documentation of immunity to varicella  (
         <a class="graphic graphic_table graphicRef108934" href="/z/d/graphic/108934.html" rel="external">
          table 5
         </a>
         ). (See
         <a class="local">
          'Moderate or severe'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/96979.html" rel="external">
          "Important health maintenance issues for children and adolescents with inflammatory bowel disease", section on 'Immunizations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Thromboembolism prophylaxis
         </strong>
         – Hospitalized children and adolescents with inflammatory bowel disease (IBD) are at increased risk for thromboembolism. Thromboembolic (TE) events in children with IBD occur during active disease, with risk factors including previous thromboembolism, major surgery, central venous catheter, older age, and use of parenteral nutrition. All hospitalized patients should be managed with nonpharmacologic interventions to minimize their risk, and those with multiple risk factors may warrant thromboprophylaxis (anticoagulation). (See
         <a class="local">
          'Surgery'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5865.html" rel="external">
          "Clinical manifestations and complications of inflammatory bowel disease in children and adolescents", section on 'Venous thromboembolism'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General monitoring and health maintenance
         </strong>
         – Comprehensive health care for children and adolescents with CD requires special considerations for monitoring growth and nutritional status, including for micronutrient deficiencies  (
         <a class="graphic graphic_table graphicRef66288" href="/z/d/graphic/66288.html" rel="external">
          table 3
         </a>
         ), infection risk, psychological issues, and cancer surveillance. (See
         <a class="medical medical_review" href="/z/d/html/96979.html" rel="external">
          "Important health maintenance issues for children and adolescents with inflammatory bowel disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5893.html" rel="external">
          "Growth failure and pubertal delay in children with inflammatory bowel disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1511079144">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Alan Leichtner, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           van Rheenen PF, Aloi M, Assa A, et al. The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update. J Crohns Colitis 2020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010; 138:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012; 61:1619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology 2021; 160:1570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scarallo L, Bolasco G, Barp J, et al. Anti-Tumor Necrosis Factor-Alpha Withdrawal in Children With Inflammatory Bowel Disease in Endoscopic and Histologic Remission. Inflamm Bowel Dis 2022; 28:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minderhoud IM, Samsom M, Oldenburg B. Crohn's disease, fatigue, and infliximab: is there a role for cytokines in the pathogenesis of fatigue? World J Gastroenterol 2007; 13:2089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kreijne JE, Lie MR, Vogelaar L, van der Woude CJ. Practical Guideline for Fatigue Management in Inflammatory Bowel Disease. J Crohns Colitis 2016; 10:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leach ST, Day AS, Messenger R, et al. Fecal Markers of Inflammation and Disease Activity in Pediatric Crohn Disease: Results from the ImageKids Study. J Pediatr Gastroenterol Nutr 2020; 70:580.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Gut 1994; 35:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362:1383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puylaert CAJ, Tielbeek JAW, Schüffler PJ, et al. Comparison of contrast-enhanced and diffusion-weighted MRI in assessment of the terminal ileum in Crohn's disease patients. Abdom Radiol (NY) 2019; 44:398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lu C, Merrill C, Medellin A, et al. Bowel Ultrasound State of the Art: Grayscale and Doppler Ultrasound, Contrast Enhancement, and Elastography in Crohn Disease. J Ultrasound Med 2019; 38:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oliva S, Thomson M, de Ridder L, et al. Endoscopy in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto IBD Group of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018; 67:414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991; 12:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Otley A, Loonen H, Parekh N, et al. Assessing activity of pediatric Crohn's disease: which index to use? Gastroenterology 1999; 116:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hyams J, Markowitz J, Otley A, et al. Evaluation of the pediatric crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr 2005; 41:416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sipponen T, Nuutinen H, Turunen U, Färkkilä M. Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES-CD. Inflamm Bowel Dis 2010; 16:2131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ledder O, Church P, Cytter-Kuint R, et al. A Simple Endoscopic Score Modified for the Upper Gastrointestinal Tract in Crohn's Disease [UGI-SES-CD]: A Report From the ImageKids Study. J Crohns Colitis 2018; 12:1073.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williet N, Sandborn WJ, Peyrin-Biroulet L. Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol 2014; 12:1246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun H, Lee JJ, Papadopoulos EJ, et al. Alternate endpoints and clinical outcome assessments in pediatric ulcerative colitis registration trials. J Pediatr Gastroenterol Nutr 2014; 58:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Otley A, Smith C, Nicholas D, et al. The IMPACT questionnaire: a valid measure of health-related quality of life in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2002; 35:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perrin JM, Kuhlthau K, Chughtai A, et al. Measuring quality of life in pediatric patients with inflammatory bowel disease: psychometric and clinical characteristics. J Pediatr Gastroenterol Nutr 2008; 46:164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Varni JW, Seid M, Rode CA. The PedsQL: measurement model for the pediatric quality of life inventory. Med Care 1999; 37:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharma Y, Bousvaros A, Liu E, Bender Stern J. Natural history of children with mild Crohn's disease. World J Gastroenterol 2019; 25:4235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mayberry JF, Lobo A, Ford AC, Thomas A. NICE clinical guideline (CG152): the management of Crohn's disease in adults, children and young people. Aliment Pharmacol Ther 2013; 37:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ardura MI, Toussi SS, Siegel JD, et al. NASPGHAN Clinical Report: Surveillance, Diagnosis, and Prevention of Infectious Diseases in Pediatric Patients With Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-α Inhibitors. J Pediatr Gastroenterol Nutr 2016; 63:130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rufo PA, Denson LA, Sylvester FA, et al. Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. J Pediatr Gastroenterol Nutr 2012; 55:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walters TD, Kim MO, Denson LA, et al. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease. Gastroenterology 2014; 146:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elson CO, Layden TJ, Nemchausky BA, et al. An evaluation of total parenteral nutrition in the management of inflammatory bowel disease. Dig Dis Sci 1980; 25:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wędrychowicz A, Zając A, Tomasik P. Advances in nutritional therapy in inflammatory bowel diseases: Review. World J Gastroenterol 2016; 22:1045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosh JR. The Current Role of Methotrexate in Patients With Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y) 2020; 16:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kugathasan S, Denson LA, Walters TD, et al. Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study. Lancet 2017; 389:1710.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfefferkorn MD, Marshalleck FE, Saeed SA, et al. NASPGHAN clinical report on the evaluation and treatment of pediatric patients with internal penetrating Crohn disease: intraabdominal abscess with and without fistula. J Pediatr Gastroenterol Nutr 2013; 57:394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hyams J, Markowitz J, Lerer T, et al. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol 2006; 4:1118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Zoeten EF, Pasternak BA, Mattei P, et al. Diagnosis and treatment of perianal Crohn disease: NASPGHAN clinical report and consensus statement. J Pediatr Gastroenterol Nutr 2013; 57:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011; 106:661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984; 86:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fell JM, Paintin M, Arnaud-Battandier F, et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. Aliment Pharmacol Ther 2000; 14:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Day AS, Whitten KE, Sidler M, Lemberg DA. Systematic review: nutritional therapy in paediatric Crohn's disease. Aliment Pharmacol Ther 2008; 27:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tjellström B, Högberg L, Stenhammar L, et al. Effect of exclusive enteral nutrition on gut microflora function in children with Crohn's disease. Scand J Gastroenterol 2012; 47:1454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Critch J, Day AS, Otley A, et al. Use of enteral nutrition for the control of intestinal inflammation in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2012; 54:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sandhu BK, Fell JM, Beattie RM, et al. Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. J Pediatr Gastroenterol Nutr 2010; 50 Suppl 1:S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borrelli O, Cordischi L, Cirulli M, et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol 2006; 4:744.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson T, Macdonald S, Hill SM, et al. Treatment of active Crohn's disease in children using partial enteral nutrition with liquid formula: a randomised controlled trial. Gut 2006; 55:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knight C, El-Matary W, Spray C, Sandhu BK. Long-term outcome of nutritional therapy in paediatric Crohn's disease. Clin Nutr 2005; 24:775.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson DC, Thomas AG, Croft NM, et al. Systematic review of the evidence base for the medical treatment of paediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2010; 50 Suppl 1:S14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanderson IR, Udeen S, Davies PS, et al. Remission induced by an elemental diet in small bowel Crohn's disease. Arch Dis Child 1987; 62:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas AG, Taylor F, Miller V. Dietary intake and nutritional treatment in childhood Crohn's disease. J Pediatr Gastroenterol Nutr 1993; 17:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newby EA, Sawczenko A, Thomas AG, Wilson D. Interventions for growth failure in childhood Crohn's disease. Cochrane Database Syst Rev 2005; :CD003873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Narula N, Dhillon A, Zhang D, et al. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2018; 4:CD000542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griffiths AM, Ohlsson A, Sherman PM, Sutherland LR. Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease. Gastroenterology 1995; 108:1056.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Afzal NA, Davies S, Paintin M, et al. Colonic Crohn's disease in children does not respond well to treatment with enteral nutrition if the ileum is not involved. Dig Dis Sci 2005; 50:1471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Afzal NA, Van Der Zaag-Loonen HJ, Arnaud-Battandier F, et al. Improvement in quality of life of children with acute Crohn's disease does not parallel mucosal healing after treatment with exclusive enteral nutrition. Aliment Pharmacol Ther 2004; 20:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stewart M, Day AS, Otley A. Physician attitudes and practices of enteral nutrition as primary treatment of paediatric Crohn disease in North America. J Pediatr Gastroenterol Nutr 2011; 52:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levine A, Milo T, Buller H, Markowitz J. Consensus and controversy in the management of pediatric Crohn disease: an international survey. J Pediatr Gastroenterol Nutr 2003; 36:464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akobeng AK. Crohn's disease: current treatment options. Arch Dis Child 2008; 93:787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilschanski M, Sherman P, Pencharz P, et al. Supplementary enteral nutrition maintains remission in paediatric Crohn's disease. Gut 1996; 38:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Belli DC, Seidman E, Bouthillier L, et al. Chronic intermittent elemental diet improves growth failure in children with Crohn's disease. Gastroenterology 1988; 94:603.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levine A, Wine E, Assa A, et al. Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial. Gastroenterology 2019; 157:440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sigall-Boneh R, Pfeffer-Gik T, Segal I, et al. Partial enteral nutrition with a Crohn's disease exclusion diet is effective for induction of remission in children and young adults with Crohn's disease. Inflamm Bowel Dis 2014; 20:1353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verma S, Kirkwood B, Brown S, Giaffer MH. Oral nutritional supplementation is effective in the maintenance of remission in Crohn's disease. Dig Liver Dis 2000; 32:769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duncan H, Buchanan E, Cardigan T, et al. A retrospective study showing maintenance treatment options for paediatric CD in the first year following diagnosis after induction of remission with EEN: supplemental enteral nutrition is better than nothing! BMC Gastroenterol 2014; 14:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Razack R, Seidner DL. Nutrition in inflammatory bowel disease. Curr Opin Gastroenterol 2007; 23:400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewis JD, Sandler RS, Brotherton C, et al. A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease. Gastroenterology 2021; 161:837.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levine A, Rhodes JM, Lindsay JO, et al. Dietary Guidance From the International Organization for the Study of Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2020; 18:1381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ritchie JK, Wadsworth J, Lennard-Jones JE, Rogers E. Controlled multicentre therapeutic trial of an unrefined carbohydrate, fibre rich diet in Crohn's disease. Br Med J (Clin Res Ed) 1987; 295:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brandes JW, Lorenz-Meyer H. [Sugar free diet: a new perspective in the treatment of Crohn disease? Randomized, control study]. Z Gastroenterol 1981; 19:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levenstein S, Prantera C, Luzi C, D'Ubaldi A. Low residue or normal diet in Crohn's disease: a prospective controlled study in Italian patients. Gut 1985; 26:989.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhattacharyya S, Shumard T, Xie H, et al. A randomized trial of the effects of the no-carrageenan diet on ulcerative colitis disease activity. Nutr Healthy Aging 2017; 4:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang P, Kim W, Zhou L, et al. Dietary fish oil inhibits antigen-specific murine Th1 cell development by suppression of clonal expansion. J Nutr 2006; 136:2391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacLean CH, Mojica WA, Newberry SJ, et al. Systematic review of the effects of n-3 fatty acids in inflammatory bowel disease. Am J Clin Nutr 2005; 82:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turner D, Shah PS, Steinhart AH, et al. Maintenance of remission in inflammatory bowel disease using omega-3 fatty acids (fish oil): a systematic review and meta-analyses. Inflamm Bowel Dis 2011; 17:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Obih C, Wahbeh G, Lee D, et al. Specific carbohydrate diet for pediatric inflammatory bowel disease in clinical practice within an academic IBD center. Nutrition 2016; 32:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen SA, Gold BD, Oliva S, et al. Clinical and mucosal improvement with specific carbohydrate diet in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2014; 59:516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mishkin B, Yalovsky M, Mishkin S. Increased prevalence of lactose malabsorption in Crohn's disease patients at low risk for lactose malabsorption based on ethnic origin. Am J Gastroenterol 1997; 92:1148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goh J, O'Morain CA. Review article: nutrition and adult inflammatory bowel disease. Aliment Pharmacol Ther 2003; 17:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brennan GT, Ha I, Hogan C, et al. Does preoperative enteral or parenteral nutrition reduce postoperative complications in Crohn's disease patients: a meta-analysis. Eur J Gastroenterol Hepatol 2018; 30:997.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Splawski JB, Pffefferkorn MD, Schaefer ME, et al. NASPGHAN Clinical Report on Postoperative Recurrence in Pediatric Crohn Disease. J Pediatr Gastroenterol Nutr 2017; 65:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta N, Cohen SA, Bostrom AG, et al. Risk factors for initial surgery in pediatric patients with Crohn's disease. Gastroenterology 2006; 130:1069.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel HI, Leichtner AM, Colodny AH, Shamberger RC. Surgery for Crohn's disease in infants and children. J Pediatr Surg 1997; 32:1063.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hansen LF, Jakobsen C, Paerregaard A, et al. Surgery and postoperative recurrence in children with Crohn disease. J Pediatr Gastroenterol Nutr 2015; 60:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boualit M, Salleron J, Turck D, et al. Long-term outcome after first intestinal resection in pediatric-onset Crohn's disease: a population-based study. Inflamm Bowel Dis 2013; 19:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kulungowski AM, Acker SN, Hoffenberg EJ, et al. Initial operative treatment of isolated ileal Crohn's disease in adolescents. Am J Surg 2015; 210:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hojsak I, Kolacek S, Hansen LF, et al. Long-term outcomes after elective ileocecal resection in children with active localized Crohn's disease--a multicenter European study. J Pediatr Surg 2015; 50:1630.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nørgård BM, Nielsen J, Qvist N, et al. Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with Crohn's disease--a nationwide cohort study. Aliment Pharmacol Ther 2013; 37:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zimmerman LA, Saites CG, Bairdain S, et al. Postoperative Complications in Children With Crohn Disease Treated With Infliximab. J Pediatr Gastroenterol Nutr 2016; 63:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitsuya JB, Gonzalez R, Thomas R, El-Baba M. The Effect of Biologics on Postoperative Complications in Children With Inflammatory Bowel Disease and Bowel Resection. J Pediatr Gastroenterol Nutr 2019; 68:334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reese GE, Purkayastha S, Tilney HS, et al. Strictureplasty vs resection in small bowel Crohn's disease: an evaluation of short-term outcomes and recurrence. Colorectal Dis 2007; 9:686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romeo E, Jasonni V, Caldaro T, et al. Strictureplasty and intestinal resection: different options in complicated pediatric-onset Crohn disease. J Pediatr Surg 2012; 47:944.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamamoto T, Keighley MR. Long-term results of strictureplasty for ileocolonic anastomotic recurrence in Crohn's disease. J Gastrointest Surg 1999; 3:555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diederen K, de Ridder L, van Rheenen P, et al. Complications and Disease Recurrence After Primary Ileocecal Resection in Pediatric Crohn's Disease: A Multicenter Cohort Analysis. Inflamm Bowel Dis 2017; 23:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baldassano RN, Han PD, Jeshion WC, et al. Pediatric Crohn's disease: risk factors for postoperative recurrence. Am J Gastroenterol 2001; 96:2169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swoger JM, Regueiro M. Evaluation for postoperative recurrence of Crohn disease. Gastroenterol Clin North Am 2012; 41:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spencer EA, Jarchin L, Rolfes P, et al. Outcomes of Primary Ileocolic Resection for Pediatric Crohn Disease in the Biologic Era. J Pediatr Gastroenterol Nutr 2021; 73:710.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hyams JS, Grand RJ, Colodny AH, et al. Course and prognosis after colectomy and ileostomy for inflammatory bowel disease in childhood and adolescence. J Pediatr Surg 1982; 17:400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99:956.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nguyen GC, Loftus EV Jr, Hirano I, et al. American Gastroenterological Association Institute Guideline on the Management of Crohn's Disease After Surgical Resection. Gastroenterology 2017; 152:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schaefer ME, Machan JT, Kawatu D, et al. Factors that determine risk for surgery in pediatric patients with Crohn's disease. Clin Gastroenterol Hepatol 2010; 8:789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griffiths AM, Wesson DE, Shandling B, et al. Factors influencing postoperative recurrence of Crohn's disease in childhood. Gut 1991; 32:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Regueiro M. Management and prevention of postoperative Crohn's disease. Inflamm Bowel Dis 2009; 15:1583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sorrentino D, Terrosu G, Avellini C, Maiero S. Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn disease. Arch Intern Med 2007; 167:1804.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Cruz P, Kamm MA, Prideaux L, et al. Mucosal healing in Crohn's disease:  a systematic review. Inflamm Bowel Dis 2013; 19:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doherty G, Bennett G, Patil S, et al. Interventions for prevention of post-operative recurrence of Crohn's disease. Cochrane Database Syst Rev 2009; :CD006873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordon M, Taylor K, Akobeng AK, Thomas AG. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease. Cochrane Database Syst Rev 2014; :CD010233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gjuladin-Hellon T, Gordon M, Iheozor-Ejiofor Z, Akobeng AK. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease. Cochrane Database Syst Rev 2019; 6:CD008414.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5866 Version 70.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33026087" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19818785" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22842618" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Mucosal healing in inflammatory bowel diseases: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33359090" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33835155" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Anti-Tumor Necrosis Factor-Alpha Withdrawal in Children With Inflammatory Bowel Disease in Endoscopic and Histologic Remission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17465453" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Crohn's disease, fatigue, and infliximab: is there a role for cytokines in the pathogenesis of fatigue?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26392414" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Practical Guideline for Fatigue Management in Inflammatory Bowel Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31899733" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Fecal Markers of Inflammation and Disease Activity in Pediatric Crohn Disease: Results from the ImageKids Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7508411" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20393175" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Infliximab, azathioprine, or combination therapy for Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30109377" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Comparison of contrast-enhanced and diffusion-weighted MRI in assessment of the terminal ileum in Crohn's disease patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30604884" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Bowel Ultrasound State of the Art: Grayscale and Doppler Ultrasound, Contrast Enhancement, and Elastography in Crohn Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30130311" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Endoscopy in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto IBD Group of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1678008" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Development and validation of a pediatric Crohn's disease activity index.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10029610" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Assessing activity of pediatric Crohn's disease: which index to use?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16205508" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Evaluation of the pediatric crohn disease activity index: a prospective multicenter experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20848462" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES-CD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29800422" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : A Simple Endoscopic Score Modified for the Upper Gastrointestinal Tract in Crohn's Disease [UGI-SES-CD]: A Report From the ImageKids Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24534550" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24121142" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Alternate endpoints and clinical outcome assessments in pediatric ulcerative colitis registration trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12394384" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The IMPACT questionnaire: a valid measure of health-related quality of life in pediatric inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18223375" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Measuring quality of life in pediatric patients with inflammatory bowel disease: psychometric and clinical characteristics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10024117" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : The PedsQL: measurement model for the pediatric quality of life inventory.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31435176" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Natural history of children with mild Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23151246" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : NICE clinical guideline (CG152): the management of Crohn's disease in adults, children and young people.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27027903" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : NASPGHAN Clinical Report: Surveillance, Diagnosis, and Prevention of Infectious Diseases in Pediatric Patients With Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-αInhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22516861" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24162032" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Increased effectiveness of early therapy with anti-tumor necrosis factor-αvs an immunomodulator in children with Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6766373" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : An evaluation of total parenteral nutrition in the management of inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26811646" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Advances in nutritional therapy in inflammatory bowel diseases: Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33867888" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : The Current Role of Methotrexate in Patients With Inflammatory Bowel Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28259484" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23783018" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : NASPGHAN clinical report on the evaluation and treatment of pediatric patients with internal penetrating Crohn disease: intraabdominal abscess with and without fistula.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16820327" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : The natural history of corticosteroid therapy for ulcerative colitis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23974063" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Diagnosis and treatment of perianal Crohn disease: NASPGHAN clinical report and consensus statement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21407187" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6140202" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10735920" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18045244" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Systematic review: nutritional therapy in paediatric Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23016828" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Effect of exclusive enteral nutrition on gut microflora function in children with Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22002478" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Use of enteral nutrition for the control of intestinal inflammation in pediatric Crohn disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20081543" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Guidelines for the management of inflammatory bowel disease in children in the United Kingdom.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16682258" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16162683" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Treatment of active Crohn's disease in children using partial enteral nutrition with liquid formula: a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15904998" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Long-term outcome of nutritional therapy in paediatric Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20081542" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Systematic review of the evidence base for the medical treatment of paediatric inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3548602" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Remission induced by an elemental diet in small bowel Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8350215" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Dietary intake and nutritional treatment in childhood Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16034910" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Interventions for growth failure in childhood Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29607496" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Enteral nutritional therapy for induction of remission in Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7698572" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16110838" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Colonic Crohn's disease in children does not respond well to treatment with enteral nutrition if the ileum is not involved.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15233696" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Improvement in quality of life of children with acute Crohn's disease does not parallel mucosal healing after treatment with exclusive enteral nutrition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20975582" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Physician attitudes and practices of enteral nutrition as primary treatment of paediatric Crohn disease in North America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12658036" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Consensus and controversy in the management of pediatric Crohn disease: an international survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18456695" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Crohn's disease: current treatment options.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8707085" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Supplementary enteral nutrition maintains remission in paediatric Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3123302" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Chronic intermittent elemental diet improves growth failure in children with Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31170412" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24983973" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Partial enteral nutrition with a Crohn's disease exclusion diet is effective for induction of remission in children and young adults with Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11215556" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Oral nutritional supplementation is effective in the maintenance of remission in Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24645851" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : A retrospective study showing maintenance treatment options for paediatric CD in the first year following diagnosis after induction of remission with EEN: supplemental enteral nutrition is better than nothing!
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17545776" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Nutrition in inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34052278" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32068150" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Dietary Guidance From the International Organization for the Study of Inflammatory Bowel Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2822203" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Controlled multicentre therapeutic trial of an unrefined carbohydrate, fibre rich diet in Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7013307" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : [Sugar free diet: a new perspective in the treatment of Crohn disease? Randomized, control study].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2996991" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Low residue or normal diet in Crohn's disease: a prospective controlled study in Italian patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28447072" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : A randomized trial of the effects of the no-carrageenan diet on ulcerative colitis disease activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16920860" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Dietary fish oil inhibits antigen-specific murine Th1 cell development by suppression of clonal expansion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16155275" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Systematic review of the effects of n-3 fatty acids in inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20564531" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Maintenance of remission in inflammatory bowel disease using omega-3 fatty acids (fish oil): a systematic review and meta-analyses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26655069" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Specific carbohydrate diet for pediatric inflammatory bowel disease in clinical practice within an academic IBD center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24897165" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Clinical and mucosal improvement with specific carbohydrate diet in pediatric Crohn disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9219788" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Increased prevalence of lactose malabsorption in Crohn's disease patients at low risk for lactose malabsorption based on ethnic origin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12562443" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Review article: nutrition and adult inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29738326" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Does preoperative enteral or parenteral nutrition reduce postoperative complications in Crohn's disease patients: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28937552" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : NASPGHAN Clinical Report on Postoperative Recurrence in Pediatric Crohn Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16618401" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Risk factors for initial surgery in pediatric patients with Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9247235" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Surgery for Crohn's disease in infants and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25373863" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Surgery and postoperative recurrence in children with Crohn disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22573565" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Long-term outcome after first intestinal resection in pediatric-onset Crohn's disease: a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25457242" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Initial operative treatment of isolated ileal Crohn's disease in adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25913894" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Long-term outcomes after elective ileocecal resection in children with active localized Crohn's disease--a multicenter European study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23190161" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Pre-operative use of anti-TNF-αagents and the risk of post-operative complications in patients with Crohn's disease--a nationwide cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27377833" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Postoperative Complications in Children With Crohn Disease Treated With Infliximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30247424" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : The Effect of Biologics on Postoperative Complications in Children With Inflammatory Bowel Disease and Bowel Resection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17854290" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Strictureplasty vs resection in small bowel Crohn's disease: an evaluation of short-term outcomes and recurrence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22595578" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Strictureplasty and intestinal resection: different options in complicated pediatric-onset Crohn disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10482715" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Long-term results of strictureplasty for ileocolonic anastomotic recurrence in Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28079626" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Complications and Disease Recurrence After Primary Ileocecal Resection in Pediatric Crohn's Disease: A Multicenter Cohort Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11467649" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Pediatric Crohn's disease: risk factors for postoperative recurrence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22500519" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Evaluation for postoperative recurrence of Crohn disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34292216" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Outcomes of Primary Ileocolic Resection for Pediatric Crohn Disease in the Biologic Era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7120008" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Course and prognosis after colectomy and ileostomy for inflammatory bowel disease in childhood and adolescence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2394349" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Predictability of the postoperative course of Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27840074" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : American Gastroenterological Association Institute Guideline on the Management of Crohn's Disease After Surgical Resection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20566311" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Factors that determine risk for surgery in pediatric patients with Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2040470" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Factors influencing postoperative recurrence of Crohn's disease in childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19322907" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Management and prevention of postoperative Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17846401" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22539420" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Mucosal healing in Crohn's disease:  a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19821389" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Interventions for prevention of post-operative recurrence of Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25081347" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31220875" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
